Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat (LBH589) and Corticosteroids for Acute Graft Versus Host Disease
NCT01111526Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2010
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in graft-versus-host disease (GVHD), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 8 months and Overall Rate of Response at 2 months. Started Apr 2010; status: completed.
02
Drugs
panobinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01111526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111526.